Literature DB >> 22983316

Placement of retrievable self-expandable metallic stents with barbs into patients with obstructive prostate cancer.

Ho-Young Song1, Choung Soo Kim, In Gab Jeong, Dalsan Yoo, Jin Hyoung Kim, Deok Ho Nam, Jae-Ik Bae, Jung-Hoon Park.   

Abstract

OBJECTIVES: To evaluate the technical feasibility and clinical effectiveness of retrievable self-expandable metallic stents with barbs in patients with obstructive prostate cancer.
METHODS: Retrievable self-expandable metallic stents with eight barbs each were inserted into eight consecutive patients with obstructive prostate cancer. Patient ages ranged from 55 to 76 years (mean, 69 years). All eight patients had previously received hormone therapy, and three had undergone palliative transurethral prostatectomy. Stents were removed using a 21-F stent removal set if they caused complications.
RESULTS: Stent placement was technically successful and well tolerated in all patients. One had severe incontinence, which improved spontaneously, and two had gross haematuria, which disappeared spontaneously within 4 days. Peak urine flow rates and post-void residual urine volumes 1 month after stent placement were 5.6-10.2 ml/s (mean, 8.3 ml/s), and 5-45 ml (mean, 27 ml), respectively. During a mean follow-up of 192 days (range, 39-632 days), one patient required stent removal after 232 days because of stone formation within the stent. No further intervention was required because the mass improved after stent removal.
CONCLUSIONS: These preliminary results suggest that retrievable stents with eight barbs are both feasible to place and effective in patients with obstructive prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22983316     DOI: 10.1007/s00330-012-2650-8

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  25 in total

1.  The relationship of palliative transurethral resection of the prostate with disease progression in patients with prostate cancer.

Authors:  Tracey L Krupski; George J Stukenborg; Kihyuck Moon; Dan Theodorescu
Journal:  BJU Int       Date:  2010-11       Impact factor: 5.588

2.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

Authors:  M J Barry; F J Fowler; M P O'Leary; R C Bruskewitz; H L Holtgrewe; W K Mebust; A T Cockett
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

3.  Covered Wallstents for palliation of malignant biliary obstruction: primary stent placement versus reintervention.

Authors:  Laura C Ornellas; Gerasimos Stefanidis; Ram Chuttani; Andres Gelrud; T Barry Kelleher; Douglas K Pleskow
Journal:  Gastrointest Endosc       Date:  2009-06-26       Impact factor: 9.427

4.  The bell-shaped nitinol prostatic stent in the treatment of lower urinary tract symptoms: experience in 108 patients.

Authors:  M M van Dijk; C A Mochtar; H Wijkstra; M P Laguna; J J M C H de la Rosette
Journal:  Eur Urol       Date:  2006-01-04       Impact factor: 20.096

5.  Evaluation of the effects of temporary covered nitinol stent placement in the prostatic urethra: short-term study in the canine model.

Authors:  Verónica Crisóstomo; Ho Young Song; Manuel Maynar; Fei Sun; Federico Soria; Juan Rafael Lima; Chang Jin Yoon; Jesús Usón-Gargallo
Journal:  Cardiovasc Intervent Radiol       Date:  2007 Jul-Aug       Impact factor: 2.740

6.  Temporary placement of covered retrievable expandable nitinol stents with barbs in high-risk surgical patients with benign prostatic hyperplasia: work in progress.

Authors:  Choung-Soo Kim; Ho-Young Song; In Gab Jeong; Hyun Jin Yeo; Eun-Young Kim; Jung-Hoon Park; Chang Jin Yoon; Sung Hyun Paick; Sang Woo Park; Jae-Ik Bae; Je Hwan Won
Journal:  J Vasc Interv Radiol       Date:  2011-08-15       Impact factor: 3.464

7.  The UroLume stent in the management of benign prostatic hyperplasia.

Authors:  E Milroy; C R Chapple
Journal:  J Urol       Date:  1993-11       Impact factor: 7.450

8.  The urolume, a permanently implanted prostatic stent for patients at high risk for surgery. Results from 5 collaborative centres.

Authors:  G Williams; C Coulange; E J Milroy; J P Sarramon; H Rubben
Journal:  Br J Urol       Date:  1993-09

9.  Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer.

Authors:  Donald S Crain; Christopher L Amling; Christopher J Kane
Journal:  J Urol       Date:  2004-02       Impact factor: 7.450

10.  The North American experience with the UroLume endoprosthesis as a treatment for benign prostatic hyperplasia: long-term results. The North American UroLume Study Group.

Authors:  J E Oesterling; S A Kaplan; H B Epstein; A J Defalco; P K Reddy; M B Chancellor
Journal:  Urology       Date:  1994-09       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.